Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EST-003
- Development stage
- Preclinical
- Lead developer
- Estrenue
- Modality
- Small Molecules
- Administration
- Intradermal, Topical, Transdermal
01
Overview
EST-003 is an early preclinical-stage formulation of minoxidil being developed by Estrenue for the treatment of hair loss (androgenetic alopecia). The drug is delivered using Estrenue's proprietary Foroderm platform, which utilizes elongated microparticles (microneedles) to physically deliver active compounds directly into the viable epidermis. This mechanical delivery bypasses the stratum corneum barrier, enhancing local drug deposition while minimizing systemic exposure. Minoxidil acts as an ATP-sensitive potassium channel opener, promoting hair growth by hyperpolarizing cell membranes, widening blood vessels, and prolonging the anagen phase of hair follicles.
- Other names
- Foroderm-delivered minoxidil
02
Targets
KCNJ8 (ATP-sensitive potassium channel subunit Kir6.1)ABCC9
Beyond the preview
Go deeper on EST-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EST-003.